Navigation Links
Gene Therapy Provides Vision to People who Were Nearly Blind

Results of Clinical Trial Supported by the Foundation Fighting Blindness

are Published in the New England Journal of Medicine

OWINGS MILLS, Md., April 27 /PRNewswire/ -- Scientists employing a gene therapy have provided partial vision to patients who were nearly blind from a condition known as Leber congenital amaurosis (LCA) -- a severe form of retinitis pigmentosa. Initial results from the clinical trial, which was funded in part by the Foundation Fighting Blindness, were published today in the New England Journal of Medicine.

All three patients, who had severely abnormal vision before entering the study, can now read several lines on an eye chart and are able to see better in dimly lit settings. One was also able to navigate better after the injection.

"This breakthrough is the greatest advancement in the 37-year history of the Foundation Fighting Blindness and the entire history of retinal degenerative disease research. We have achieved a critical milestone in curing a form of childhood blindness," says Gordon Gund, Co-Founder and Chairman of the Foundation Fighting Blindness, which is the largest non-governmental source of funding for this research.

"Our clinical trial results represent an important first step in developing therapies and treatments that will reverse blindness in people with a variety of retinal degenerative diseases," says Jean Bennett, M.D., Ph.D., who is the study's lead researcher at The Children's Hospital of Philadelphia.

"The three participants in the Foundation-supported study at The Children's Hospital of Philadelphia are ages 19-26. Though the trial's main goal was to evaluate safety of the treatment, the research team is very excited about the participants' improvements in vision," says Stephen Rose, Ph.D., Chief Research Officer, Foundation Fighting Blindness.

This Phase I study will continue through its planned enrollment of nine individuals between the ages of 8 and 27. The success in the first three patients, however, will position the researchers well to plan Phase II clinical studies to evaluate the treatment's potential effectiveness in younger children who were born blind from LCA. The investigators believe the treatment has the potential to give near-normal vision to these children.

The first step toward the development of this treatment began with the discovery of the RPE65 gene in 1993. In 2000, the first dog born blind from LCA, a Briard named Lancelot, was successfully treated with gene therapy, and has been seeing well since then with just a single treatment. More than 50 dogs have now been treated successfully and are all seeing well. Clinical trials of the procedure began in October 2007 at the Foundation-funded Children's Hospital of Philadelphia (CHOP)-Penn Pediatric Center for Retinal Degenerations in Philadelphia.

More than 10 million people across the United States are affected by retinal degenerative diseases which include: macular degeneration, retinitis pigmentosa, and Usher syndrome.

About the Foundation Fighting Blindness

The Foundation Fighting Blindness ( is the largest source of non-governmental funding for retinal degenerative disease research in the world. The urgent mission of the Foundation Fighting Blindness is to drive the research that will provide preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration, Usher syndrome, and the entire spectrum of retinal degenerative diseases.

SOURCE Foundation Fighting Blindness
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
2. FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
3. In Blood Vessel Stents, Innovative Materials Allow Better Control, Delivery of Gene Therapy
4. Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells
5. ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science
6. MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
7. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
8. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
9. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
10. NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
11. Early Research Suggests Umbilical Cord Blood Cell Therapy May Reduce Progression of Alzheimers Disease
Post Your Comments:
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... , June 23, 2016 , ... Thursday, July 7, 2016 , , , , LOCATION: , ... , , , , EXPERT PANELISTS:  , , , Frost ... Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh ... The global pharmaceutical industry is witnessing an exceptional era. Several ...
(Date:6/23/2016)... 2016  Guerbet announced today that it has been ... Award . One of 12 suppliers to ... its support of Premier members through exceptional local customer ... commitment to lower costs. ... our outstanding customer service from Premier," says Massimo ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... The ... OSHA Training Institute Education Center headquartered in Northern California, has issued an important ... heat at their worksites. Employers with workers exposed to high temperatures should ...
(Date:6/27/2016)... ... ... "FCPX editors can now reveal their media with growing colorful split screen ... - CEO of Pixel Film Studios. , ProSlice Color brings the split screens ... reveal the media of their split screens with growing colorful panels. , ProSlice Color ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... today its affiliation with Tennessee Counseling Association. This new relationship allows ... the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... cutting edge technology to revolutionize the emergency ambulance transport experience for the millions ... aware of how Uber has disrupted the taxi industry through the use of ...
Breaking Medicine News(10 mins):